 Teri Schreiner
Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 31 | 2023 | 384 | 4.800 |
Why?
| | Neuromyelitis Optica | 4 | 2023 | 112 | 1.340 |
Why?
| | Myelitis | 4 | 2020 | 88 | 1.020 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.850 |
Why?
| | Cerebral Veins | 1 | 2021 | 16 | 0.790 |
Why?
| | Immunosuppressive Agents | 5 | 2023 | 681 | 0.790 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 100 | 0.750 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 64 | 0.750 |
Why?
| | Microvessels | 1 | 2021 | 77 | 0.750 |
Why?
| | Nervous System Diseases | 4 | 2019 | 261 | 0.700 |
Why?
| | Sarcoidosis | 1 | 2021 | 130 | 0.690 |
Why?
| | Venous Thrombosis | 1 | 2021 | 147 | 0.690 |
Why?
| | Enterovirus Infections | 5 | 2020 | 164 | 0.640 |
Why?
| | Movement Disorders | 1 | 2017 | 45 | 0.590 |
Why?
| | Muscular Diseases | 1 | 2017 | 107 | 0.580 |
Why?
| | Dimethyl Fumarate | 1 | 2016 | 10 | 0.560 |
Why?
| | HLA-DRB1 Chains | 5 | 2023 | 97 | 0.460 |
Why?
| | Gene-Environment Interaction | 3 | 2023 | 201 | 0.440 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2019 | 68 | 0.430 |
Why?
| | Demyelinating Diseases | 3 | 2023 | 79 | 0.430 |
Why?
| | Child | 32 | 2023 | 19129 | 0.420 |
Why?
| | Genetic Predisposition to Disease | 6 | 2023 | 2275 | 0.410 |
Why?
| | Adolescent | 28 | 2023 | 18480 | 0.400 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 73 | 0.400 |
Why?
| | Paralysis | 3 | 2016 | 67 | 0.380 |
Why?
| | Central Nervous System Viral Diseases | 2 | 2020 | 63 | 0.340 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 3 | 2023 | 44 | 0.340 |
Why?
| | Vaccines | 1 | 2014 | 380 | 0.330 |
Why?
| | Neuromuscular Diseases | 2 | 2020 | 90 | 0.330 |
Why?
| | Aquaporin 4 | 3 | 2023 | 87 | 0.320 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 31 | 0.320 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1515 | 0.310 |
Why?
| | Humans | 52 | 2023 | 118974 | 0.300 |
Why?
| | Autoantibodies | 4 | 2023 | 1335 | 0.300 |
Why?
| | Male | 36 | 2023 | 57801 | 0.290 |
Why?
| | Cognitive Dysfunction | 2 | 2022 | 301 | 0.290 |
Why?
| | Cognition Disorders | 2 | 2022 | 529 | 0.290 |
Why?
| | Case-Control Studies | 11 | 2023 | 3171 | 0.290 |
Why?
| | Adjuvants, Immunologic | 2 | 2020 | 207 | 0.280 |
Why?
| | Immunologic Factors | 2 | 2019 | 225 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 7 | 2023 | 3174 | 0.270 |
Why?
| | Vaccination | 1 | 2014 | 1222 | 0.270 |
Why?
| | Rituximab | 3 | 2022 | 155 | 0.250 |
Why?
| | Vitamin D | 2 | 2019 | 354 | 0.250 |
Why?
| | Treatment Outcome | 4 | 2020 | 9342 | 0.250 |
Why?
| | Female | 33 | 2023 | 61565 | 0.240 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 76 | 0.240 |
Why?
| | Environmental Exposure | 2 | 2018 | 405 | 0.240 |
Why?
| | Age of Onset | 6 | 2023 | 467 | 0.230 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 19 | 0.220 |
Why?
| | Immunoglobulin G | 3 | 2022 | 788 | 0.210 |
Why?
| | Recurrence | 5 | 2023 | 975 | 0.200 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4596 | 0.190 |
Why?
| | Risk Factors | 11 | 2023 | 9000 | 0.190 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 25 | 0.190 |
Why?
| | Muscle Weakness | 1 | 2020 | 82 | 0.180 |
Why?
| | Enterovirus | 1 | 2019 | 72 | 0.170 |
Why?
| | Glatiramer Acetate | 1 | 2019 | 20 | 0.170 |
Why?
| | Education, Special | 1 | 2018 | 19 | 0.170 |
Why?
| | Oxidoreductases | 1 | 2019 | 100 | 0.170 |
Why?
| | Fluoxetine | 1 | 2018 | 47 | 0.160 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2062 | 0.160 |
Why?
| | Electromyography | 2 | 2017 | 326 | 0.160 |
Why?
| | Disability Evaluation | 2 | 2020 | 280 | 0.160 |
Why?
| | Disabled Persons | 1 | 2020 | 147 | 0.160 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 398 | 0.160 |
Why?
| | Disease Susceptibility | 2 | 2017 | 331 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2023 | 770 | 0.160 |
Why?
| | Child, Preschool | 8 | 2020 | 9491 | 0.150 |
Why?
| | Neural Conduction | 1 | 2017 | 81 | 0.150 |
Why?
| | Atrophy | 1 | 2017 | 164 | 0.150 |
Why?
| | Recovery of Function | 1 | 2020 | 604 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2018 | 132 | 0.140 |
Why?
| | Attitude | 1 | 2017 | 231 | 0.140 |
Why?
| | Developmental Disabilities | 1 | 2018 | 247 | 0.140 |
Why?
| | Transgender Persons | 2 | 2016 | 135 | 0.140 |
Why?
| | Sodium Chloride, Dietary | 1 | 2016 | 49 | 0.130 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2015 | 12 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2017 | 209 | 0.130 |
Why?
| | Dietary Fats | 1 | 2017 | 322 | 0.130 |
Why?
| | Perception | 1 | 2017 | 314 | 0.130 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 252 | 0.130 |
Why?
| | Colorado | 4 | 2019 | 4196 | 0.130 |
Why?
| | Gonadal Steroid Hormones | 1 | 2016 | 122 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2019 | 597 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2023 | 12978 | 0.120 |
Why?
| | Paraplegia | 1 | 2014 | 60 | 0.120 |
Why?
| | Bone Remodeling | 1 | 2015 | 64 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2017 | 220 | 0.120 |
Why?
| | Adult | 12 | 2023 | 31512 | 0.120 |
Why?
| | Motor Neurons | 1 | 2016 | 213 | 0.120 |
Why?
| | Bacterial Vaccines | 1 | 2014 | 60 | 0.120 |
Why?
| | Administration, Oral | 1 | 2016 | 756 | 0.120 |
Why?
| | CD40 Antigens | 1 | 2014 | 80 | 0.120 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 130 | 0.110 |
Why?
| | Hypersensitivity | 1 | 2017 | 268 | 0.110 |
Why?
| | United States | 9 | 2021 | 12555 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2018 | 654 | 0.110 |
Why?
| | Viral Vaccines | 1 | 2014 | 90 | 0.110 |
Why?
| | MicroRNAs | 1 | 2019 | 637 | 0.110 |
Why?
| | Neuroimaging | 1 | 2014 | 256 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2674 | 0.110 |
Why?
| | Medication Adherence | 1 | 2017 | 556 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2014 | 396 | 0.100 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 126 | 0.100 |
Why?
| | Testosterone | 1 | 2015 | 351 | 0.100 |
Why?
| | Bone Density | 1 | 2015 | 449 | 0.100 |
Why?
| | Patient Outcome Assessment | 2 | 2023 | 122 | 0.100 |
Why?
| | Disease Progression | 3 | 2023 | 2490 | 0.100 |
Why?
| | Body Composition | 1 | 2015 | 653 | 0.100 |
Why?
| | Transcription Factors | 1 | 2019 | 1570 | 0.100 |
Why?
| | Feeding Behavior | 1 | 2016 | 601 | 0.090 |
Why?
| | Prospective Studies | 5 | 2020 | 6471 | 0.090 |
Why?
| | Ultraviolet Rays | 2 | 2023 | 381 | 0.090 |
Why?
| | Death, Sudden | 1 | 2009 | 33 | 0.090 |
Why?
| | Disease Outbreaks | 3 | 2019 | 322 | 0.090 |
Why?
| | Diet | 1 | 2017 | 1153 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 10793 | 0.090 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 140 | 0.090 |
Why?
| | Body Mass Index | 1 | 2017 | 2092 | 0.090 |
Why?
| | Vena Cava, Inferior | 1 | 2009 | 55 | 0.090 |
Why?
| | Constriction, Pathologic | 1 | 2009 | 203 | 0.080 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 60 | 0.080 |
Why?
| | Testicular Neoplasms | 1 | 2009 | 95 | 0.080 |
Why?
| | Alleles | 2 | 2023 | 832 | 0.080 |
Why?
| | Sweden | 2 | 2017 | 63 | 0.080 |
Why?
| | Genotype | 2 | 2023 | 1882 | 0.080 |
Why?
| | Neuropsychological Tests | 2 | 2022 | 1032 | 0.070 |
Why?
| | Risk | 2 | 2019 | 853 | 0.070 |
Why?
| | Haplotypes | 2 | 2019 | 473 | 0.060 |
Why?
| | Influenza, Human | 1 | 2010 | 554 | 0.060 |
Why?
| | Cohort Studies | 3 | 2020 | 5116 | 0.060 |
Why?
| | Cognition | 2 | 2022 | 1024 | 0.060 |
Why?
| | Infant | 4 | 2020 | 8293 | 0.060 |
Why?
| | Fingolimod Hydrochloride | 1 | 2023 | 32 | 0.060 |
Why?
| | Memory and Learning Tests | 1 | 2022 | 1 | 0.060 |
Why?
| | Middle Aged | 6 | 2020 | 27617 | 0.060 |
Why?
| | Azathioprine | 1 | 2022 | 51 | 0.060 |
Why?
| | Logistic Models | 2 | 2018 | 1901 | 0.050 |
Why?
| | Pandemics | 1 | 2010 | 1355 | 0.050 |
Why?
| | Demography | 1 | 2023 | 274 | 0.050 |
Why?
| | Biomarkers | 3 | 2019 | 3588 | 0.050 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1323 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 380 | 0.050 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 128 | 0.050 |
Why?
| | Hospitalization | 1 | 2010 | 1785 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 226 | 0.050 |
Why?
| | HLA Antigens | 1 | 2023 | 230 | 0.050 |
Why?
| | Sunlight | 1 | 2021 | 60 | 0.050 |
Why?
| | HIV Infections | 1 | 2015 | 2459 | 0.050 |
Why?
| | Antigens, CD20 | 1 | 2020 | 28 | 0.050 |
Why?
| | Prevalence | 2 | 2017 | 2326 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 4552 | 0.050 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | HLA-A3 Antigen | 1 | 2019 | 6 | 0.040 |
Why?
| | HLA-B7 Antigen | 1 | 2019 | 8 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 4708 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
| | Aged | 4 | 2019 | 19657 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 24 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2023 | 688 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 827 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 159 | 0.040 |
Why?
| | Propensity Score | 1 | 2020 | 242 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 59 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 344 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 667 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 310 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 245 | 0.040 |
Why?
| | Habits | 1 | 2017 | 38 | 0.040 |
Why?
| | Geography, Medical | 1 | 2017 | 11 | 0.040 |
Why?
| | California | 1 | 2019 | 382 | 0.040 |
Why?
| | Knowledge | 1 | 2017 | 59 | 0.040 |
Why?
| | Water Quality | 1 | 2017 | 29 | 0.040 |
Why?
| | Family | 1 | 2021 | 585 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 239 | 0.040 |
Why?
| | Reading | 1 | 2018 | 157 | 0.040 |
Why?
| | Diet Surveys | 1 | 2017 | 85 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2017 | 48 | 0.040 |
Why?
| | Vegetables | 1 | 2017 | 133 | 0.040 |
Why?
| | North America | 1 | 2017 | 266 | 0.030 |
Why?
| | Binding Sites | 1 | 2019 | 1224 | 0.030 |
Why?
| | Gender Identity | 1 | 2016 | 102 | 0.030 |
Why?
| | Brain | 2 | 2019 | 2490 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 334 | 0.030 |
Why?
| | Genetic Testing | 1 | 2017 | 389 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 983 | 0.030 |
Why?
| | Air Pollution | 1 | 2017 | 209 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 996 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1687 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 104 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1474 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2513 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 366 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 481 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2014 | 224 | 0.030 |
Why?
| | Cell Separation | 1 | 2014 | 296 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 699 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2017 | 648 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1597 | 0.030 |
Why?
| | Muscle Strength | 1 | 2015 | 283 | 0.030 |
Why?
| | Animals | 1 | 2014 | 33381 | 0.030 |
Why?
| | Acute Disease | 1 | 2014 | 940 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2014 | 1085 | 0.020 |
Why?
| | Autopsy | 1 | 2009 | 89 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6412 | 0.020 |
Why?
| | Parents | 1 | 2017 | 1212 | 0.020 |
Why?
| | Autoimmunity | 1 | 2014 | 831 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 544 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2009 | 241 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4709 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3003 | 0.020 |
Why?
| | Asthma | 1 | 2017 | 2158 | 0.010 |
Why?
| | Age Factors | 1 | 2010 | 2995 | 0.010 |
Why?
|
|
Schreiner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|